We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Nanopore Technologies Plc | ONT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -3.90 | -2.91% | 130.00 | 16:35:24 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 134.00 | 129.20 | 134.10 | 130.00 | 133.90 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 24/7/2024 07:04 by bamboo2 24 July 2024Oxford Nanopore Technologies plc Half Year Trading Update · Trading in-line with both revenue and gross margin guidance in the face of challenging end-markets · Building commercial momentum heading into the second half reinforces confidence; full year 2024 and medium-term guidance reaffirmed Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or "the Group"), the company delivering a new generation of molecular sensing technology based on nanopores, today provides a trading update for the six months ended 30 June 2024 ahead of results, which will be published on 3 September 2024. The Group expects to report Life Sciences Research Tools (LSRT) revenue for the six months ended 30 June 2024 of approximately £84 million (H1 2023: £86.0 million), broadly flat year-on-year at constant currency; marginally down (2%) on a reported basis, including foreign exchange headwinds. Underlying[1] LSRT revenue, grew by 12.4% on a constant currency basis year-on-year. Growth for the first half of 2024 is in-line with expected 2024 phasing. Underlying growth has been strongest across the PromethION franchise[2], across all product lines. Underlying growth was delivered across each region, and it was strongest across EMEAI and APAC, with commercial momentum building for the second half, supported by new product launches, a number of new and expanded contracts, and a step up in sales team productivity in the second quarter. Gross margin for the first half is expected to show year-on-year improvement, despite foreign exchange headwinds, and remains on track to meet the Group's full year 2024 guidance. Outlook Full year 2024 guidance remains unchanged: - LSRT revenue growth is expected to be between 6 and 15% on a constant currency basis and underlying revenue growth is expected to be between 20 and 30% on a constant currency basis. The Group continues to expect FY 2024 revenue to be second half weighted, with an approximate 45:55 split. - Gross margin is expected to be approximately 57%. All medium-term (FY 2027) guidance is unchanged. Gordon Sanghera, Chief Executive Officer, commented: "Our first half performance is in-line with our expectations. We delivered robust underlying revenue growth, despite a challenging macroeconomic backdrop. "We enter the second half in a strong position; new contract wins coupled with the increased productivity of our sales teams in the second quarter reinforces our confidence in our full year 2024 outlook. In addition, the launch of new products from our regulated pipeline, including GridION Q-Line and ElysION, our sample-to-answer automated sequencing solution, will drive adoption in new clinical and applied markets in the near and medium-term." |
Posted at 23/7/2024 08:22 by bamboo2 RNS NON 23/7/2024Oxford Nanopore Technologies plc Oxford Nanopore and Plasmidsaurus announce collaboration and multi-year, multi-million dollar contract expansion Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and Plasmidsaurus, the LA-based company that introduced overnight whole-plasmid sequencing, today announce a new strategic collaboration to advance plasmid sequencing beyond legacy methods, and an expanded multi-year, multi-million dollar global contract. Plasmidsaurus' whole-plasmid sequencing is used by researchers and industry professionals around the world for a broad spectrum of applications, from basic research to industrial applications, gene therapy, vaccine development, genetic engineering and more. Its sequencing capabilities are based on Oxford Nanopore's real-time, long-read sequencing technology, which has enabled Plasmidsaurus to set new standards for quality and speed, delivering overnight results and richer datasets that unlock more accurate, comprehensive, and reliable insights. The extension of the existing contract will see the collaboration continue to take share of a fast-growing estimated $1.5B market opportunity in synthetic biology as nanopore-based sequencing continues to displace traditional methods, such as Sanger, for plasmid sequencing. Founded in 2021, Plasmidsaurus has since opened nine labs in three countries and is expanding its global network of 660 dropboxes and labs in key biotech hubs, including new locations in the US, Europe, and Asia. Plasmidsaurus became an Oxford Nanopore customer in 2021. As strategic collaborators going forward, Oxford Nanopore and Plasmidsaurus also intend to co-develop new technologies, reagents, and applications beyond plasmid sequencing, including microbial and gene therapy use cases, to best meet evolving market needs, providing further market share opportunities. Gordon Sanghera, CEO of Oxford Nanopore commented: "By collaborating with Plasmidsaurus, we are advancing the fields of synthetic biology and biotechnology through the unique capabilities of nanopore technology that are not possible with legacy methods. Our joint efforts will drive significant market growth and deliver best-in-class sequencing services to a global audience." |
Posted at 03/6/2024 18:05 by bamboo2 ONT at ESHG today, this is the agenda for discussion,Such is the interest in ONT kit, it's standing room only again. This was the situation at LC2024 too. Let's hope the newly expanded sales team can make something out of this interest, and next months outlook is back to expectations. |
Posted at 23/5/2024 08:38 by bamboo2 London Calling Technology UpdateAnnouncements highlighted breakthrough technology performance and updates to Oxford Nanopore's IVD pipeline at annual customer conference 23 May 2024 Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Company"), the company delivering a new generation of nanopore-based molecular sensing technology, presented breakthrough performance data and new platform updates at the Company's annual London Calling customer conference, held between 21 and 24 May 2024. During the sold-out event, with more than 5,500 registered on-line and in-person participants, the Company also provided updates to its clinical product pipeline, unveiling a new roadmap for its first IVD product ahead of its first clinical and biopharma day on Friday. Technology updates included: · Delivering increasingly rich, high performance multiomic data: The update focused on improved performance on accuracy, delivering complete genomes with nanopore-only Telomere-to-Telomere (T2T) sequencing, and full-length chromosomes in a single read, illustrated by successful T2T reads of four yeast chromosomes as proof of concept. · Improving direct RNA sequencing to support breakthrough science and biopharma workflows: higher accuracy and output for direct RNA sequencing alongside the example of integrated, real-time quality control (QC) test for mRNA vaccines. · Pipeline updates, enabling ultra-high output and accessible, distributed sequencing for anyone, anywhere: with the MinION Mk1D entering early access, continued progression with TraxION, enabling portable library prep in the field, the Voltage chip for ultra-rapid whole genome sequencing (WGS) and the new prototype of Oxford Nanopore's smallest sequencer to date - the SmidgION - which was on display at the event. A written summary and a video replay of the technology talk can be accessed on the Oxford Nanopore website here. This morning, the Company will present a product review including an update on progress to its regulated product pipeline. In addition to locked-down Q line devices, the GridION is expected to meet ISO 13485 standards in 2025 and the Company will seek CE-IVD certification in the EU after that. The device will be available for specified partners only. The GridION Q-Line product range is on track to launch shortly in Q3-2024, as previously announced. Alongside the technology updates the Company will also provide more details at its first clinical and biopharma day on Friday. |
Posted at 15/4/2024 15:45 by yasx 74tom13 Apr '24 - 13:10 - 1262 of 1272Interestingly, if you were to use the 425p IPO price as the high instead, then the 78.6% "bottom rung" fib would be at 91p too. I suspect ONT would have plenty of suitors, both UK based & internationally, at well above the current price. -------------------- Not only do you suspect it, but you hope that is the case since I recall you have been plugging this all the way down from 300p. I have never met anyone with as robust and consistent track record of failure as that of 74Tom - whatever stock he calls a buy disintegrates into dust. ONT is one of his better picks since it remains listed. Most of his picks just go to the wall resulting in a total wipeout. I was taking a look here today with a view to taking a long position and his presence on this thread is sufficient to induce a considerable degree of caution before I have even delved into the minutiae of ONT. If 74Tom is long of any company, well, caveat emptor. He is undoubtedly the perfect contrarian indicator. |
Posted at 11/4/2024 13:26 by bamboo2 2 April 2024An evolution of Nanopore next-generation sequencing technology: implications for medical microbiology and public health Next-generation sequencing has evolved as a powerful tool, with applications that extend from diagnosis to public health surveillance and outbreak investigations. Short-read sequencing, using primarily Illumina chemistry, has been the prevailing approach. Single-molecule sensing and long-read sequencing using Oxford Nanopore Technologies (ONT) has witnessed a breakthrough in the evolution of the technology, performance, and applications in the past few years. In this issue of the Journal of Clinical Microbiology, Bogaerts et al. (hxxps://doi.org/10. |
Posted at 23/3/2024 12:01 by bamboo2 Price action is far from ideal.This is a weak sector at present. Hopefully it should change at some point, as massive expansion of sequencing around the world is forecast. The UK market is discounting many growth and tech stocks, and analysts have taken against ONT management and their attempts to be realistic in the face of unexpected problems, such as the ban on export of devices containing NVDA chips to China. On the positive side, ONT has almost completed the planned increases of staff in technical, manufacturing and sales functions. Naturally, this should increase turnover. Accuracy continues to improve and customer sentiment is at all time highs. The new ASIC should get an airing in May 2024. Management have so far made no attempt to extend the life of LAT shares that expire in June 2024, which means takeover potential could lift the valuation. There are a large number of organisations around the world that could currently buy the whole company for pocket money. I find ONT one of the most exciting companies in the UK, and despite a losing position at present will continue to hold for the long term. |
Posted at 09/1/2024 07:03 by bamboo2 Pretty much on target.==================== Oxford Nanopore Technologies plc FY23 trading update 09 January 2024 Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Group"), the company delivering a new generation of nanopore-based molecular sensing technology, today provides a trading update ahead of reporting its full-year 2023 results on 6 March. FY23 financial performance The Group expects to report LSRT revenue for the 12 months ended 31 December 2023 of approximately £169 million (FY22: £146.8 million), representing year-on-year growth of approximately 15% on a reported basis and 15% on a constant currency basis. Underlying LSRT revenue growth, excluding revenue from Emirati Genome Program ("EGP") and COVID-19 sequencing, is expected to be approximately 39% on a constant currency basis. Strong performance across the broader customer base in FY23 was driven by consumables[1] sales, which accounted for approximately 75% of revenue. Underlying revenue growth in the second half is expected to be approximately 32%, impacted by slower than expected ramp up of certain new S3 customers. Expected revenue from these customers in FY23 will now fall into FY24. In addition, there was some slow-down in growth in China and in the Middle East following issuance of the recent US semiconductor trade rule further regulating sales of advanced AI semiconductors. Product development plans within 2024 include updates that are expected to mitigate this headwind. In addition to financial reporting, there was other evidence of market traction and disruption. For example, the Group leased or sold more than 700 PromethION 2 Solos (P2 Solo) in FY23; Oxford Nanopore's most recently launched product represents a new market area of affordable, accessible and high output sequencing. Material associated revenue is anticipated to pull through with consumables sales in FY24 and future periods. Emirati Genome Program update The Group has signed an agreement to replace and supersede the existing purchase agreement it has with G42 Laboratories LLC ("G42") in support of the EGP. The new agreement will provide greater flexibility to achieve the programme objectives and reflects the parties' desire to refocus on clinical uses of the platform, that can utilise the platform's unique benefits of richer and faster data. G42 and Oxford Nanopore have agreed to collaborate to leverage the richer data and speed of Oxford Nanopore's technology in areas of unmet clinical need such as developmental disorders, rare human genetic diseases and neonatal intensive care. The EGP contract, originally announced on 9 November 2021 with a total value of approximately $68 million over a three-year period, has generated revenues of approximately $43.5 million to date, including amounts payable in relation to the amended contract. The new agreement will remove the outstanding purchase commitment from the original agreement and extends the expiration date until 31 December 2026. EGP revenue in 2024 and beyond is not anticipated to be a material portion of revenue and as such, the Group will cease reporting EGP revenue separately following FY23 results. Revenue related to the EGP in 2023 (under the original and revised agreement) was approximately £12 million, in-line with guidance. Excluding EGP, the Group's gross margin in FY23 would have been expected to be more than 57%, in-line with guidance. However, as a result of the agreement with G42, the Group's FY23 gross margin is expected to be in the range 53 to 55%. Gross margin in future periods is not expected to be affected by this amendment. Medium-term Outlook All medium-term (FY26) targets are unchanged: The Group continues to expect underlying revenue growth of more than 30% per annum on a constant currency basis, consistent with the Group's recent performance. The Group's medium-term gross margin target of greater than 65% for FY26 is also unchanged. Margin expansion is expected to be driven primarily by operational improvements already underway and/or planned including improved manufacturing processes, recycling of electrical components and automation. The Group continues to target adjusted EBITDA breakeven by the end of 2026. This will be achieved through revenue growth and margin expansion, detailed above, and disciplined operating expenditure. [ENDS] |
Posted at 10/11/2023 08:56 by bamboo2 This paper goes a long way to explaining why the ongoing UK clinical trial of Illuminas GRAIL should be shown the door, because it is ineffective, slow, expensive and outdated compared with ONT's long read capability.==================== Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing. The paper explained Problem Current sequencing methods based on short-read technologies to analyze cell-free DNA (cfDNA) as a liquid biopsy in cancer patients have limitations. These include a bias toward shorter cfDNA populations and long waiting times for data. The Oxford Nanopore Technologies (ONT) platform offers a portable and fast alternative, capable of sequencing any length of cfDNA fragment. However, its potential for analyzing cfDNA from cancer patients remains underexplored. Results Plasma and urine samples from lung and bladder cancer patients, as well as healthy controls, were sequenced with a MinION ONT and compared to a short-read sequencer. The ONT platform successfully retrieved cfDNA somatic copy number aberrations within 24 h of sampling, and with comparable sensitivity to short-read technologies. The study also demonstrated that ONT sequencing could recover long cfDNA fragments in both plasma and urine samples, contrary to the canonical belief that cfDNA is predominantly short and fragmented. The presence of tumor-derived signal in these long fragments is confirmed in not only humans but also using a xenograft model. In addition to the size profile, other fragmentomic features could be retrieved from the cfDNA data. Impact In conclusion, the ONT sequencing provided a fast and accurate analysis of cfDNA from liquid biopsy samples. It allowed the detection of copy number aberrations, estimation of tumor fraction, and recovery of long cfDNA fragments. The ONT platform's deployability and short turnaround time make it a promising tool for liquid biopsy analysis. |
Posted at 19/5/2023 07:05 by bamboo2 19 May 2023Oxford Nanopore Technologies plc London Calling Technology Update Breakthrough technology performance generates richer information for research and clinical analyses, and pathway to enabling sequencing by anyone, anywhere 19 May 2023 Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Company"), the company delivering a new generation of Nanopore-based molecular sensing technology, presented breakthrough performance data and new platform updates, including direct RNA sequencing to support the emergence of RNA-based therapies, at the Company's annual London Calling customer conference, held between 17 and 19 May 2023. Technology updates included: Record-breaking performance and rapid sequencing, across the nanopore sequencing platform: Following the early access rollout of "Q20+" chemistry in 2022, Oxford Nanopore sequencing technology has now broken records in performance, providing more biological information than traditional platforms, rapidly and at any scale. The platform now enables the characterisation of telomere-to-telomere genomes, the sequencing of single nucleotide variants (SNVs) as well as, or better, than traditional technologies, in addition to the characterisation of structural variation, complex copy number variants and real-time gold standard methylation. This year "Q20+" chemistry moved from early access to released stage. -- Improved performance: While the latest "Q20+" sequencing performance using the Simplex method continues to consistently deliver high performance for most genomic applications, the technology update included record-breaking performance data for more challenging projects using Duplex. Duplex exceeds Q30/99.9% single molecule accuracy irrespective of read length and will become more widely available in a controlled commercial launch. -- Richer data: The Company highlighted an expanded machine learning model to enable real-time, high-accuracy epigenetic insights in all contexts, including plants and bacteria, delivering on the promise to sequence any DNA modification in any genome. Pipeline: enabling accessible, distributed sequencing for anyone, anywhere Oxford Nanopore continues to innovate towards a new future of near-sample, real-time, low-cost technology that can characterise biological samples in any environments from clinics to factories to classrooms. -- High-output, small format: The PromethION 2 Solo rollout continues, opening up new high-output sequencing possibilities with compact form factor. Developer access to the PromethION 2i, with integrated compute and screen, starts now and will continue through the year. -- New MinION - with iPad [i] connectivity: The MinION sequencer has been revamped for the first time since 2015 and will continue to enable a broad scientific community to take control of their high-performance experiments, rapidly and in any environment. The new MinION MkID will also offer easy seamless connection to an iPad Pro, enabling it to use all the latest features including long battery life, accelerated processing, 5G mobile connectivity and more. Developer access starts later this year. -- Smaller formats: In development and now showing "Q20+" sequencing, a new, small and low-power chip (application specific integrated circuit - ASIC) will further drive the ability to analyse anything, anywhere. This new ASIC will underpin a new family of lower-cost, lower-power devices, including the MinION MkII while the standard MinION ASIC is also being revamped to deliver data more quickly. Direct RNA sequencing launch, available in Q3 2023 RNA, the messenger molecule that carries genetic information from DNA and directs the synthesis of proteins, has traditionally been sequenced by conversion to cDNA. New understanding of RNA's functional significance - and related emergence in RNA-based therapies including vaccines - has underscored the importance of RNA-related research. Oxford Nanopore is the first to enable direct sequencing of the native molecule, and in doing so reveals more biology including RNA base modifications. -- New RNA chemistry: Oxford Nanopore has introduced a new kit and flow cell for direct RNA sequencing for increased accuracy and output, with the potential to unlock a new field of biological analysis. This update will enable significant advancements in the RNA research market alongside novel applications of direct single molecule sensing such as mRNA vaccine research, where non-natural RNA bases used in their development need to be sequenced. Single molecule raw-read accuracy has increased significantly, while output has improved 3-4x compared to existing Oxford Nanopore RNA sequencing chemistry. Simplifying products and workflows to support broader usage To support different users taking advantage of nanopore sequencing, innovations are being introduced to simplify and make more accessible the end-to-end sequencing process. These includes provision of easy-to-use data analysis tools in EPI2ME, the analytics tool set provided by Oxford Nanopore. -- Easier interface to support more applications: EPI2ME supports increasingly broad applications, from infectious disease, biopharma quality control testing, human variations and single cell. This enhanced interface equips users at all levels of expertise with the information they need, wherever they are. New features also include the ability to run on local hardware or seamlessly integrate with cloud compute. Pipeline: enabling ultra-high output, high-quality nanopore sequencing The PromethION 48 is already capable of delivering nearly 10,000 genomes per year, at two human genomes per flow cell, from $345 per genome[ii]. Oxford Nanopore highlighted improvements to high-output sequencing with the PromethION line to support users with larger programmes, large sample numbers, or service providers in high-output applications. -- Increased output: The Company highlighted the immense headroom still available in the platform that will be delivered overtime utilising new pipeline enzymes (that pass DNA through a nanopore faster), for increased output and improvements to run buffers. With greater speeds there is the potential to deliver as many as four human genomes from a single PromethION Flow Cell and up to 20,000 genomes per year. Replay of the t echnology update presentation A written summary and video replay of the technology talk can be accessed on the Oxford Nanopore website at: Analyst and Investor Call On Monday, 22 May 2023, at 3pm BST/10am EDT , Gordon Sanghera, Chief Executive Officer and Rosemary Sinclair Dokos, SVP Product and Programme Management will host a webcast and conference call with analysts and investors to discuss the technology update session from London Calling and address questions. The webcast can be accessed on Oxford Nanopore's website at or via this link . The webcast will be recorded and a replay will be available via the same link shortly after the event. For conference call details please contact ir@nanoporetech.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
